Janus Henderson Group PLC Grows Position in Biohaven Ltd. (NYSE:BHVN)

Janus Henderson Group PLC raised its position in Biohaven Ltd. (NYSE:BHVN) by 12.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,982,425 shares of the company’s stock after purchasing an additional 756,032 shares during the quarter. Janus Henderson Group PLC owned 6.91% of Biohaven worth $260,735,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Biohaven by 8.1% in the fourth quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company’s stock valued at $314,267,000 after buying an additional 628,211 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Biohaven by 0.8% in the fourth quarter. Stifel Financial Corp now owns 6,559,313 shares of the company’s stock valued at $244,990,000 after buying an additional 50,052 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Biohaven by 21.6% in the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock valued at $165,392,000 after buying an additional 785,578 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock valued at $73,922,000 after buying an additional 1,169,721 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Biohaven by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company’s stock valued at $71,182,000 after buying an additional 190,754 shares in the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BHVN shares. JPMorgan Chase & Co. lowered their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Morgan Stanley lowered their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $54.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a “buy” rating in a research note on Thursday, March 20th. Finally, Robert W. Baird lowered their price objective on Biohaven from $60.00 to $57.00 and set an “outperform” rating for the company in a research note on Monday, April 28th. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $62.54.

Insider Transactions at Biohaven

In related news, Director John W. Childs purchased 32,700 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 16.00% of the company’s stock.

Biohaven Trading Down 0.2%

Shares of BHVN opened at $20.20 on Monday. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -2.16 and a beta of 1.18. The stock has a 50 day moving average of $23.44 and a 200-day moving average of $35.24. Biohaven Ltd. has a 52 week low of $15.79 and a 52 week high of $55.70.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, sell-side analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.